67-4

69/90

journal.pone.0223113. eCollection 2019. 40) Nagayama H, Kano O, Murakami H, Ono K, Hamada M, Toda T, Sengoku R, Shimo Y, Hattori N: Effect of istradefylline on mood disorders in Parkinson’s disease. J Neurol Sci, 2019 Jan 15; 396: 78-83. doi: 10.1016/j.jns.2018. 11.005. Epub 2018 Nov 5. PubMed PMID: 30423541. 41) Nakamura T, Sekimoto S, Oyama G, Shimo Y, Hattori N, Kajimoto H: Pilot feasibility study of a semi-automated three-dimensional scoring system for cervical dystonia. PLoS One, 2019 Aug 8; 14: e0219758. doi:10.1371/journal.pone. 0219758. eCollection 2019. PubMed PMID: 31393884; PubMed Central PMCID: PMC6687132.＊ 42) Nakayama S, Shimonaka S, Elahi M, Nishioka K, Oji Y, Matsumoto SI, Li Y, Yoshino H, Mogushi K, Hatano T, Sato T, Ikura T, Ito N, Motoi Y, Hattori N: Novel two mutations in MAPT enhancing tau aggregation and seeding activity in the patients with motor neuron disease, progressive parkinsonism and cogni-tive decline. Neurobiol Aging, 2019; 84: 240.e13-240.e22, doi: 10.1016/j.neurobiolaging.2019. 02.016. 43) Nishioka K, Suzuki M, Nakajima M, Hara T, Iseki M, Hattori N: Painful legs and moving toes syndrome evaluated through brain single photon emission computed tomography: a case series. J Neurol, 2019 Mar; 266: 717-725. doi:10.1007/s00415-019-09194-3. Epub 2019 Jan 14. PubMed PMID: 30637456. 44) Ochiishi T, Kaku M, Kiyosue K, Doi M, Urabe T, Hattori N, Shimura H, Ebihara T: New Alzheimer’s disease model mouse specialized for analyzing the function and toxicity of intraneuronal Amyloid β oligomers. Sci Rep, 2019 Nov 22; 9: 17368. doi: 10.1038/s41598-019-53415-8. 45) Okuzumi A, Hatano T, Kamagata K, Hori M, Mori A, Oji Y, Taniguchi D, Daida K, Shimo Y, Yanagisawa N, Nojiri S, Aoki S, Hattori N: Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson’s disease? Eur J Neurol, 2019 Nov; 26: 1408-1416. doi: 10.1111/ene.14009. ＊ 46) Okuzumi A, Hatano T, Ueno SI, Ogawa T, Saiki S, Mori A, Koinuma T, Oji Y, Ishikawa KI, Fujimaki M, Sato S, Ramamoorthy S, 47) Osada T, Ohta S, Ogawa A, Tanaka M, Suda A, Kamagata K, Hori M, Aoki S, Shimo Y, Hattori N, Shimizu T, Enomoto H, Hanajima R, Ugawa Y, Konishi S: An Essential Role of the Intraparietal Sulcus in Response Inhibi-tion Predicted by Parcellation-Based Network. J Neurosci, 2019 Mar 27; 39: 2509-2521. doi: 10.1523/JNEUROSCI.2244-18.2019. Epub 2019 Jan 28. PubMed PMID: 30692225; PubMed Central PMCID: PMC6435821. 48) Ouchi Y, Sasaki J, Arai H, Yokote K, Harada K, Katayama Y, Urabe T, Uchida Y, Hayashi M, Yokota N, Nishida H, Otonari T, Arai T, Sakuma I, Sakabe K, Yamamoto M, Kobayashi T, Oikawa S, Yamashita S, Rakugi H, Imai T, Tanaka S, Ohashi Y, Kuwabara M, Ito H: Ezetimibe Lipid-Lowering Trial on Preven-tion of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75): A Random-ized Controlled Trial. Circulation, 2019; 140: 992-1003. 49) Saccenti L, Andica C, Hagiwara A, Yokoyama K, Takemura MY, Fujita S, Maekawa T, Kamagata K, Le Berre A, Hori M, Hattori N, Aoki S: Brain tissue and myelin volumetric analysis in multiple sclerosis at 3T MRI with various in-plane resolutions using synthetic MRI. Neuroradiology, 2019 Nov; 61: 1219-1227. doi: 10.1007/s00234-019-02241-w. 50) Saiki S, Sasazawa Y, Fujimaki M, Kamagata K, Kaga N, TakaH, Li Y, Souma S, Hatano T, Imamichi Y, Furuya N, Mori A, Oji Y, Ueno S-I, Nojiri S, Miura Y, Ueno T, Funayama M, Aoki S, Hattori N: A metabolic profile of poly-amines in Parkinson’s disease: a promising biomarker. Ann Neurol, 2019 Aug; 86: 251-263. doi: 10.1002/ana.25516. 51) Sato K, Aita N, Hokari Y, Kitahara E, Tani M, Izawa N, Hatori K, Nakamura R, Sasaki F, Sekimoto S, Jo T, Oyama G, Hatano T, Shimo Y, Iwamuro H, Umemura A, Hattori N, Fuji-wara T: Balance and Gait Improvements of Postoperative Rehabilitation in Patients with Parkinson’s Disease Treated with Subtha-lamic Nucleus Deep Brain Stimulation (STN-Mohney RP, Hattori N: Metabolomics-based identification of metabolic alterations in PARK2. Ann Clin Transl Neurol, 2019 Feb 21; 6: 525- 536. doi: 10.1002/acn3.724. 389